TB-500 is usually sold as "thymosin beta-4." Most people take that at face value. But the name gets used for two different molecules, and one weighs more than five times what the other does. Same name. Not the same thing.
TB-500 usually isn't thymosin beta-4. It's one small piece of it.
Thymosin beta-4 is a natural peptide, 43 amino acids long. TB-500, the way the name's usually used, is a seven-amino-acid stretch copied from its middle. Most of the research people quote was done on the whole thing. And the name isn't held to one meaning. Some sellers put it on the whole molecule.
The proof: one blade, or the whole knife
Let's get into it.
Picture a Swiss Army knife. Thymosin beta-4 is the whole knife. TB-500 is one blade, popped off and sold on its own. The blade still cuts. It's just not the knife.
The blade is real, and NIH found it. Thymosin beta-4's big job inside a cell is holding onto actin, the protein cells use to change shape and move. Part of that grip sits in a seven-amino-acid stretch, LKKTETQ. In 2003, a team at the National Institutes of Health tested the molecule piece by piece. In their lab tests on moving cells, that seven-piece stretch matched the whole molecule (Philp et al., FASEB J 2003). On that one job.
One catch: TB-500 is the blade with a cap on it. TB-500 is that same stretch with a small chemical cap, an acetyl group, on its front end. In 2024, a Korean doping-control lab tested TB-500 itself on fibroblasts, the cells that close a scratch in a dish. The capped seven-piece didn't make a significant difference. One of its smaller breakdown pieces did (Rahaman et al., J Chromatogr B 2024). A blade working in one test doesn't prove the version in the vial does.
But the knife has other tools. The front end of thymosin beta-4 carries a different short piece, Ac-SDKP, with its own separate research (Sosne et al., FASEB J 2010). A fragment from the middle has none of it. And the human research? The whole molecule has been tested in people, mostly as eye drops, including late-stage (phase 3) dry-eye trials of a version called RGN-259, one with 700 patients (ARISE-3, ClinicalTrials.gov). One published mid-stage trial had nine patients (Sosne et al., Cornea 2015). It still isn't approved. The fragment's first registered human trial only started recruiting in 2026, and it has no published results yet (ClinicalTrials.gov).
So why should you care? Weight doesn't lie. Molecules are weighed in daltons, which is just the unit chemists use. PubChem, the NIH's chemistry database, lists TB-500 at 889 (PubChem) and thymosin beta-4 at 4,963 (PubChem). Roughly 900 or roughly 5,000. That gap is exactly what an LC-MS identity test measures, and it's how a lab confirms which molecule is actually in a vial.
"Does it matter if a TB-500 vial holds the whole thing?" Yes. It's a different molecule with different research behind it. Studies of the knife don't describe the blade, and studies of the blade don't describe the knife.
The big learning lesson
Keep reading: BPC-157 and TB-500: why they're studied together · Three-peptide vs four-peptide blends: what's in each · The FDA "peptide ban" of 2026, explained
Frequently asked questions
Is TB-500 the same as thymosin beta-4?
Not usually. Thymosin beta-4 is a natural 43-amino-acid peptide. TB-500 most often means a synthetic seven-amino-acid piece of it, Ac-LKKTETQ, though some sellers use the name for the full molecule.
How can I tell which molecule is in a vial labeled TB-500?
By weight. The fragment is roughly 900 daltons. Full-length thymosin beta-4 is roughly 5,000. An LC-MS identity test measures that difference.
Is TB-500 FDA approved?
No, and neither is thymosin beta-4. An FDA advisory committee recommended TB-500 for the pharmacy compounding list in July 2026, but that vote isn't an approval. Both are prohibited by the World Anti-Doping Agency.